Medicure Inc (V:MPH) — Market Cap & Net Worth
Market Cap & Net Worth: Medicure Inc (MPH)
Medicure Inc (V:MPH) has a market capitalization of $20.08 Million (CA$27.76 Million) as of September 19, 2026. Listed on the V stock exchange, this Canada-based company holds position #25202 globally and #988 in its home market, demonstrating a 2.70% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Medicure Inc's stock price CA$2.66 by its total outstanding shares 10436313 (10.44 Million). Also see balance sheet size of Medicure Inc for a full breakdown of the balance sheet.
Medicure Inc Market Cap History: 2015 to 2026
Medicure Inc's market capitalization history from 2015 to 2026. Data shows change from $32.09 Million to $20.08 Million (-2.48% CAGR). Also see Medicure Inc (MPH) cash conversion ratio for how efficiently the company converts equity into cash flow.
Medicure Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Medicure Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check Medicure Inc stock quote for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
0.30x
Medicure Inc's market cap is 0.30 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $77.76 Million | $37.78 Million | $27.66 Million | 2.06x | 2.81x |
| 2017 | $56.24 Million | $27.13 Million | $43.42 Million | 2.07x | 1.30x |
| 2018 | $46.43 Million | $29.11 Million | $3.93 Million | 1.59x | 11.83x |
| 2019 | $33.22 Million | $20.17 Million | -$19.79 Million | 1.65x | N/A |
| 2020 | $8.98 Million | $11.61 Million | -$6.84 Million | 0.77x | N/A |
| 2021 | $6.95 Million | $21.74 Million | -$727.00K | 0.32x | N/A |
| 2022 | $7.62 Million | $23.07 Million | $1.36 Million | 0.33x | 5.59x |
| 2023 | $10.57 Million | $21.69 Million | -$922.00K | 0.49x | N/A |
| 2024 | $6.64 Million | $21.91 Million | -$1.04 Million | 0.30x | N/A |
| 2025 | $8.61 Million | $28.86 Million | -$7.10 Million | 0.30x | N/A |
Competitor Companies of MPH by Market Capitalization
Companies near Medicure Inc in the global market cap rankings as of September 19, 2026. Review MPH tangible net assets ratio to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Medicure Inc by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #518 globally with a market cap of $52.60 Billion USD.
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #613 globally with a market cap of $44.92 Billion USD.
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #635 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #670 globally with a market cap of $40.99 Billion USD ( CN¥280.10 Billion CNY).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #518 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #613 | GALDERMA GROUP AG | NYSE:GALDY | $44.92 Billion | $38.53 |
| #635 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €16.90 |
| #670 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $40.99 Billion | CN¥43.91 |
Medicure Inc Historical Marketcap From 2015 to 2026
Between 2015 and today, Medicure Inc's market cap moved from $32.09 Million to $ 20.08 Million, with a yearly change of -2.48%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CA$20.08 Million | +133.33% |
| 2025 | CA$8.61 Million | +29.55% |
| 2024 | CA$6.64 Million | -37.14% |
| 2023 | CA$10.57 Million | +38.61% |
| 2022 | CA$7.62 Million | +9.78% |
| 2021 | CA$6.95 Million | -22.69% |
| 2020 | CA$8.98 Million | -72.95% |
| 2019 | CA$33.22 Million | -28.46% |
| 2018 | CA$46.43 Million | -17.45% |
| 2017 | CA$56.24 Million | -27.67% |
| 2016 | CA$77.76 Million | +142.35% |
| 2015 | CA$32.09 Million | -- |
End of Day Market Cap According to Different Sources
On Sep 19th, 2026 the market cap of Medicure Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $20.08 Million USD |
| MoneyControl | $20.08 Million USD |
| MarketWatch | $20.08 Million USD |
| marketcap.company | $20.08 Million USD |
| Reuters | $20.08 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Medicure Inc
Medicure Inc., a biopharmaceutical company, engages in the research, development, and commercialization of human therapies in the United States. The company markets AGGRASTAT injection, a glycoprotein GP IIb/IIIa receptor antagonist for the treatment of acute coronary syndrome, including unstable angina and non-Q-wave myocardial infarction. It also offers ZYPITAMAG to treat patients with primary … Read more